Economics

Two-Dose Hepatitis B Vaccination Expected To Reduce Costs In Long Run

Published in Hepatitis Weekly, September 3rd, 2001

by Sonia Nichols, senior medical writer - Even though the cost of a two-dose regimen of hepatitis B vaccine may be more for adolescents in the short term, in the long run, it could save money, encourage more vaccination compliance, and lower infection rates, researchers say.

Those researchers, members of a North American research consortium, developed a decision analysis model to predict costs and lifetime outcomes when administering a 2-dose hepatitis B virus (HBV) vaccine regimen to adolescents in public schools, public health clinics, and private sector settings.

The analysis compared the predicted costs of administering two-dose regimens with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-09-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry